Home  |  Top News  |  Most Popular  |  Video  |  Multimedia  |  News Feeds  |  Feedback
  Medicine  |  Nature & Earth  |  Biology  |  Technology & Engineering  |  Space & Planetary  |  Psychology  |  Physics & Chemistry  |  Economics  |  Archaeology
Top > Medicine, Health Care > Researchers Find Risk Markers for… >

Researchers Find Risk Markers for Erectile Dysfunction Following Radiation in Prostate Cancer

Published: September 27, 2012.
Released by The Mount Sinai Hospital / Mount Sinai School of Medicine  

In the first study of its kind, a research team led by Mount Sinai School of Medicine and Albert Einstein College of Medicine of Yeshiva University discovered 12 genetic markers associated with the development of erectile dysfunction (ED) in prostate cancer patients who were treated with radiation. The findings, to be published online September 27, 2012, in advance of the October 1, 2012 print issue in the International Journal of Radiation Oncology• Biology• Physics, the official scientific journal of the American Society for Radiation Oncology, are an important step towards helping clinicians determine the best course of treatment for prostate cancer patients and may lead to the development of therapies that alleviate side effects.

The main treatments for prostate cancer – surgery, brachytherapy (seed implants) and external beam radiation therapy – are all very effective at curing prostate cancer. Unfortunately, each treatment places patients at risk for ED. According to the National Cancer Institute, the prevalence of erectile dysfunction following external beam radiation for prostate cancer ranges from 65 percent to 85 percent. The Prostate Cancer Foundation estimates prevalence of ED following seed therapy at 25 to 50 percent. Many men will be able to regain their potency with time and treatments, but doctors would like to identify which men may be more likely to develop this side effect.

In the first large scale Genome-Wide Association Study to identify single nucleotide polymorphisms (SNPs) associated with susceptibility for the development of erectile dysfunction following radiotherapy for prostate cancer, researchers conducted a two-part study, first, to discover the candidate genetic markers of side effect risk, and second, to confirm which of those markers are replicated in a second group of patients. In the first group of prostate cancer patients, which included 132 men who developed erectile dysfunction after radiotherapy and 103 men similarly treated who did not develop erectile dysfunction, they found a set of genetic markers associated with erectile dysfunction. In the second part of the study, which examined 128 patients who developed erectile dysfunction after radiotherapy and 102 who did not, researchers confirmed that 12 SNPs were associated with erectile dysfunction.

"Thankfully, current treatments for prostate cancer offer excellent rates of long-term survival, so patients and their physicians have a choice about which treatment path to take," said Barry Rosenstein, PhD, Professor of Radiation Oncology, Mount Sinai School of Medicine. "However, the risk of developing erectile dysfunction after radiation treatment is highly variable, suggesting there may be a genetic component to determining that risk. Our study confirms that specific markers make certain patients more susceptible to this side effect."

Patients in the study cohort were given one of three treatments: internal radiotherapy, known as brachytherapy; brachytherapy plus external beam radiation; or external beam radiation alone. They were followed for an average length of nearly four years to determine level of sexual function after treatment.

Interestingly, the 12 SNPs identified in this study were located near genes that seem to be related to erectile function rather than related to radiation response. The researchers conclude that these SNPs may affect genes that sensitize a patient to developing erectile dysfunction when exposed to radiation during therapy.

"Prostate cancer screening and treatment are undergoing major shifts," said Harry Ostrer, MD, Professor of Pathology and Genetics at Albert Einstein College of Medicine and Director of Genetic and Genomic Testing at Montefiore Medical Center and co-principal investigator of the study. "This is part of our ongoing effort to identify men at highest risk for disease, identify the aggressive tumors that would be responsive to therapy, and to improve quality of life for men with indolent prostate cancers who might benefit from active surveillance, rather than therapy."

The authors indicate that examination of a large, independent cohort of similarly treated patients will be necessary to definitively determine which SNPs to include as part of a clinically useful predictive test to identify which men are at greatest risk for developing erectile dysfunction following prostate cancer radiotherapy. The researchers are also evaluating the impact of radiation treatment on urinary complications and proctitis, the inflammation of the rectum.

The above story is based on materials provided by The Mount Sinai Hospital / Mount Sinai School of Medicine.

Translate this page: Chinese French German Italian Japanese Korean Portuguese Russian Spanish

comments powered by Disqus

Related »

Adding Radiation to Hormone Therapy for Prostate Cancer Treatment Will Increase Survival Chances
Prostate cancer patients who are treated with a combination of hormone therapy and radiation have a substantially improved chance …
Increased Radiation Offers No Survival Benefit for Patients with Low-risk Prostate Cancer
PHILADELPHIA - Increased radiation dose is associated with higher survival rates in men with medium- and high-risk prostate cancer, …
Predicting Erectile Dysfunction from Prostate Cancer Treatment
Researchers have identified 12 DNA sequences that may help doctors determine which men will suffer from erectile dysfunction (ED) …
Hormone Therapy May Be Hazardous for Men with Heart Conditions
Fairfax, Va., July 26, 2011 – Adding hormone therapy to radiation therapy has been proven in randomized clinical trials …
How Prostate Cancer Therapies Compare by Cost And Effectiveness
The most comprehensive retrospective study ever conducted comparing how the major types of prostate cancer treatments stack up to …
Most Prostate Cancer Specialists Don't Recommend Active Surveillance for Low-risk Patients
June 16, 2014 – Specialists who treat prostate cancer agree that active surveillance is an effective option—yet most don't …
Combined Radiation And Hormonal Therapy Improves Survival in Node-positive Prostate Cancer
A new study finds that men with prostate cancer that has spread to nearby lymph nodes, who have a …
Aspirin Use Associated with Lower Risk of Cancer Death for Men with Prostate Cancer
Men with prostate cancer who take anticoagulants like aspirin in addition to radiation therapy or surgery may be able …
Study Finds Diagnosing Physicians Influence Therapy Decisions for Prostate Cancer Patients
New research from The University of Texas MD Anderson Cancer Center is shedding light on the important role a …
Oxygen in Tumors Predicts Prostate Cancer Recurrence
Low oxygen levels in tumors can be used to predict cancer recurrence in men with intermediate-risk prostate cancer even …
Short-term Hormone Therapy Plus Radiation Therapy Increases Survival for Men with Early-stage Prostate Cancer
Philadelphia — Short-term hormone therapy (androgen deprivation therapy: ADT) given in combination with radiation therapy for men with early-stage …
Active Surveillance of Intermediate-risk Prostate Cancer Associated with Decreased Survival
ALEXANDRIA, Va. - An analysis of data on 945 patients with prostate cancer that is managed with active surveillance …
Surgery Found Effective for Patients with Aggressive Prostate Cancer
ROCHESTER, Minn. -- In one of the first studies to focus exclusively on the outcomes after treatment for patients …
Variations in Key Gene Predict Cancer Patients' Risk for Radiation-induced Toxicity
(NEW YORK – July 8, 2014) Key genetic variants may affect how cancer patients respond to radiation treatments, according …
Dose-escalated Hypofractionated IMRT, Conventional IMRT for Prostate Cancer Have Like Side Effects
Fairfax, Va., April 3, 2014—Dose-escalated intensity modulated radiation therapy (IMRT) with use of a moderate hypofractionation regimen (72 Gy …
More » 
© Newsline Foundation  |  About  |  Privacy Policy  |  Feedback  |  Mobile